Anemia

Exploratory analysis of CERA data shows sustained and stable control of anemia

Published in Blood Weekly, July 7th, 2005

New data from a year-long phase II study have shown that CERA (continuous erythropoietin receptor activator), an investigational antianemia agent being developed by Roche, provided sustained and stable control of hemoglobin levels with dosing intervals of up to 4 weeks in dialysis patients who suffer from anemia.

These data were presented during the European Renal Association - European Dialysis and Transplant Association congress in Istanbul, Turkey. Phase II results with CERA are being confirmed in an extensive phase III clinical program.

"These findings suggest that CERA may represent a convenient treatment alternative with less-frequent dosing,"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-07-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry